Find Reports

Select Report Type

Reimbursement Review

Displaying 51 - 75 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Opdivo	nivolumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Stage IIB or IIC melanoma, adjuvant	Reimburse with clinical criteria and/or conditions	Complete	Nov 6, 2023	May 29, 2024	PC0339-000
Awiqli	insulin icodec	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Diabetes mellitus, type 2	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 17, 2024	SR0790-000
Bimzelx	bimekizumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 19, 2023	May 16, 2024	SR0809-000
Bimzelx	bimekizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Psoriatic arthritis	Reimburse with clinical criteria and/or conditions	Complete	Oct 5, 2023	May 15, 2024	SR0803-000
Myalepta	metreleptin	Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Leptin deficiency in lipodystrophy	Reimburse with clinical criteria and/or conditions	Complete	Jul 25, 2023	May 9, 2024	SR0784-000
Doptelet	avatrombopag	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Chronic immune thrombocytopenia (ITP)	Do not reimburse	Complete	Feb 3, 2022	May 8, 2024	SR0721-000
Adtralza	tralokinumab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	atopic dermatitis (AD)	Do not reimburse	Complete	Jun 5, 2023	May 8, 2024	SR0787-000
Jemperli	dostarlimab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Endometrial cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 18, 2023	May 3, 2024	PC0325-000
Libtayo	cemiplimab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Locally advanced or metastatic NSCLC (first line)	Reimburse with clinical criteria and/or conditions	Complete	Sep 27, 2023	May 2, 2024	PC0331-000
Remsima	infliximab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Crohn’s disease	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 22, 2024	SR0816-000
Leqvio	inclisiran	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Primary hypercholesterolemia	Do not reimburse	Complete	Sep 19, 2023	Apr 22, 2024	SR0791-001
Livmarli	maralixibat	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Alagille syndrome	Reimburse with clinical criteria and/or conditions	Complete	May 5, 2023	Apr 22, 2024	SR0780-000
Remsima	infliximab	Recommendation and Reason Patient and Clinician Group input	Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 22, 2024	SR0816-001
Hemgenix	etranacogene dezaparvovec	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Hemophilia B	Reimburse with clinical criteria and/or conditions	Complete	Oct 4, 2023	Apr 19, 2024	SG0805-000
N/A	panitumumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder input	Left-sided metastatic colorectal cancer (mCRC)	Reimburse with clinical criteria and/or conditions	Complete	May 19, 2023	Apr 18, 2024	PX0333-000
Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Lennox-Gastaut Syndrome (LGS)	Reimburse with clinical criteria and/or conditions	Complete	Sep 20, 2023	Apr 18, 2024	SR0800-000
Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group Input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Dravet Syndrome (DS)	Reimburse with clinical criteria and/or conditions	Complete	Sep 25, 2023	Apr 18, 2024	SR0799-000
Epidiolex	cannabidiol	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Seizures associated with Tuberous Sclerosis Complex (TSC)	Reimburse with clinical criteria and/or conditions	Complete	Sep 29, 2023	Apr 18, 2024	SR0798-000
N/A	everolimus	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Responses to Questions From the Drug Programs Stakeholder Input	Renal angiomyolipoma associated with tuberous sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 6, 2023	Apr 18, 2024	SX0814-000
Paxlovid	nirmatrelvir/ritonavir	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Mild-to-moderate COVID-19, treatment	Reimburse with clinical criteria and/or conditions	Complete	Sep 15, 2023	Apr 11, 2024	SR0808-000
Tecvayli	teclistamab	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation Patient and Clinician Group input	Relapsed or refractory multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Aug 31, 2023	Apr 8, 2024	PC0332-000
Slynd	drospirenone	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Contraceptive, oral	Reimburse with clinical criteria and/or conditions	Complete	Aug 14, 2023	Mar 18, 2024	SR0806-000
Uplizna	inebilizumab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Neuromyelitis optica spectrum disorders (NMOSD)	Reimburse with clinical criteria and/or conditions	Complete	Aug 18, 2023	Mar 13, 2024	SR0793-000
Ultomiris	ravulizumab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Neuromyelitis optica spectrum disorder (NMOSD)	Reimburse with clinical criteria and/or conditions	Complete	Aug 29, 2023	Mar 13, 2024	SR0785-000
Lonsurf	trifluridine and tipiracil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Metastatic colorectal cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 15, 2023	Feb 29, 2024	PC0330-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 589

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Alternate level of care (ALC)			Aug 26, 2024	Optimal Use	Active	OP0557-000
Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections		Efficacy and Safety of Treatment Options for Uncomplicated Gonococcal Infections Summary Report	Aug 19, 2024	Rapid Review with Expert Input	Completed	RD0070-000
Review of Guidelines on Clonidine for Various Indications		Review of Guidelines on Clonidine for Various Indications	Aug 19, 2024	Rapid Review	Completed	RC1543-000
The Canadian Medical Imaging Inventory: 2022–2023		Canadian Medical Imaging Inventory 2022– 2023: CT Canadian Medical Imaging Inventory 2022– 2023: MRI Canadian Medical Imaging Inventory 2022– 2023: PET-CT and PET-MRI Canadian Medical Imaging Inventory 2022–2023: SPECT and SPECT-CT Canadian Medical Imaging Inventory 2022–2023: Provincial and Territorial Overvi…Canadian Medical Imaging Inventory 2022–2023: The Medical Imaging Team Canadian Medical Imaging Inventory 2022– 2023: Methods The Canadian Medical Imaging Inventory 2022–2023 - Evidence Preview	Aug 13, 2024	Technology Review	Completed	HC0024-000
Evidence Review of Treatment Options for Uncomplicated Gonococcal Infections		Final Report Summary Report	Aug 6, 2024	Technology Review	Completed	RE0046-000
Re-Treatment With Immune Checkpoint Inhibitors		Final Report	Aug 6, 2024	Summary with Critical Appraisal	Completed	RC1544-000
Drug Shortages in Canada		Final Report	Jul 31, 2024	Environmental Scan	Completed	ES0381-000
Opioid Analgesics to Treat Chronic Noncancer Pain among Patients Prescribed Opioid Agonist Therapy or With Opioid Use Disorder	Our systematic review examined 5 observational studies on the safety of opioid analgesics alone or with opioid agonist therapy for chronic pain in patients with opioid use disorder or a history of opioid use disorder.	Summary Report Final Report Supplemental Document Project Protocol	Jul 23, 2024	Systematic Review	Completed	RE0045-000
Auditory Verbal Therapy for Children with Hearing Loss		Auditory Verbal Therapy for Children with Hearing Loss	Jul 19, 2024	Rapid Review	Completed	RC1542-000
Optimizing ultrasound booking schedules			Jul 16, 2024		In Progress	CM0021-000
Somatropin		Final Report	Jul 12, 2024	Technology Review	Completed	HC0068-000
Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy	Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.	Final Report	Jul 11, 2024	Technology Review	Complete	HC0063-000
Optimal installation of DI equipment			Jun 28, 2024		In Progress	CM0013-000
Appraisal of RWE submitted for health technology assessment			Jun 28, 2024		In Progress	MG0028-000
PET-CT Comparisons 2020-2024			Jun 28, 2024		In Progress	CM0006-000
Cystic Fibrosis			Jun 28, 2024		In Progress	HM0005-000
Newborn screening - Drugs for Rare Diseases Strategy			Jun 28, 2024	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement Reviews			Jun 28, 2024		In Progress	MG0027-000
Drug Shortages in Canada - Delphi Panel			Jun 28, 2024	Technology Review	In Progress	HC0074-000
Choline Supplementation for Infants, Children, and Pregnant People		Choline Supplementation for Infants, Children, and Pregnant People	Jun 18, 2024	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome	Jun 17, 2024	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer Pain		Nabilone for Chronic Non-Cancer Pain	Jun 14, 2024	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities	Jun 14, 2024	Rapid Review	Completed	RC1536-000
Minimum Retesting Intervals for Lab Tests	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance Report Technology Review - Minimum Retesting Intervals for Lab Tests Lipase Quick Guide Hemoglobin A1C Quick Guide Thyroid Stimulating Hormone Quick Guide Serum Protein Electrophoresis Quick Guide Antinuclear Antibody Quick Guide	Jun 11, 2024	Technology Review	Completed	HC0078-000
Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy		Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy	Jun 7, 2024	Rapid Review	Completed	RC1534-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 111

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Electrospun Healing Fibres for the Management of Burns and Wounds	Electrospun Healing Fibres for the Management of Burns and Wounds	Mar 23, 2022	Health Technology Update	Completed	EN0033-000
2022 Health Technology Trends to Watch	2022 Health Technology Trends to Watch	Mar 16, 2022	Roundup	Completed	ER0012-000
Artificial Intelligence for the Prediction of Sepsis in Adults	Artificial Intelligence for the Prediction of Sepsis in Adults	Mar 14, 2022	Health Technology Update	Completed	EN0034-000
Vacuum-Induced Uterine Tamponade for Postpartum Hemorrhage	Vacuum-Induced Uterine Tamponade for Postpartum Hemorrhage	Mar 8, 2022	Health Technology Update	Active	EN0035-000
Emerging Drugs for Amyotrophic Lateral Sclerosis	Emerging Drugs for Amyotrophic Lateral Sclerosis	Mar 1, 2022	Emerging Health Technologies	Completed	EH0100-000
Emerging Drugs for Generalized Myasthenia Gravis	Horizon Scan	Feb 24, 2022	Emerging Health Technologies	Completed	EH0099-000
An Overview of Smartphone Apps	Horizon Scan	Feb 22, 2022	Emerging Health Technologies	Completed	EH0098-000
Renal Denervation for People with Hypertension	Health Technology Update	Jan 17, 2022	Health Technology Update	Completed	EN0038-000
Self-Sampling Devices for HPV Testing	Horizon Scan	Dec 21, 2021	Emerging Health Technologies	Completed	EH0101-000
An Overview of Emerging Point-of-Care Tests for Differentiating Bacterial and Viral Infections	An Overview of Emerging Point-of-Care Tests for Differentiating Bacterial and V…	Dec 14, 2021	Emerging Health Technologies	Completed	EH0097-000
Adaptive Deep Brain Stimulation for the Treatment of Parkinson Disease and Essential Tremor	Adaptive Deep Brain Stimulation for the Treatment of Parkinson Disease and Esse…	Dec 2, 2021	Health Technology Update	Completed	EN0036-000
Neuromodulation Technologies for the Treatment of Alzheimer Disease	Neuromodulation Technologies for the Treatment of Alzheimer Disease	Sep 27, 2021	Emerging Health Technologies	Completed	EH0095-000
An Overview of Post‒COVID-19 Condition (Long COVID)	An Overview of Post‒COVID-19 Condition (Long COVID)	Sep 24, 2021	Emerging Health Technologies	Completed	EH0096-000
Pharyngeal Electrical Stimulation Device for the Treatment of Dysphagia Associated With Neurologic Conditions	Pharyngeal Electrical Stimulation Device for the Treatment of Dysphagia Associ…	Sep 22, 2021	Health Technology Update	Completed	EN0030-000
Barricaid Spinal Implant Device	Horizon Scan Newsletter	Aug 16, 2021	Health Technology Update	Completed	EN0032-000
Breath Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2	Breath Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus…	Aug 6, 2021	Health Technology Update	Completed	EN0039-000
Portable Neuromodulation Stimulator for chronic balance or gait impairment	Horizon Scan Newsletter	Aug 6, 2021	Health Technology Update	Completed	EN0031-000
Combined Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza	Combined Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Influe…	Jun 30, 2021	Health Technology Update	Completed	EN0029-000
Wearable Respiratory Sensor for the Detection of Opioid-Induced Respiratory Depression	EN0028 Respmeter Newsletter Final.pdf	Jun 15, 2021	Health Technology Update	Completed	EN0028-000
Direct to Patient Virtual Visits	An Overview of Direct-to-Patient Virtual Visits in Canada	Jun 4, 2021	Emerging Health Technologies	Completed	EH0091-000
Framework for Drugs for Rare Diseases	es0355-drugs-for-rare-diseases-pw.pdf	May 6, 2021	Environmental Scan	Completed	ES0355-000
2021 Health Technology Trends to Watch	ER0011 Horizon Scanning 2021 Tech Trends v8.0.pdf	Feb 4, 2021	Roundup	Completed	ER0011-000
Rapid Point-of-Care Testing for COVID-19	Rapid Point-of-Care Testing for COVID-19	Dec 18, 2020	Emerging Health Technologies	Complete	RB1536-000 - EH0093-000
Serological Tests for COVID-19	Serological Tests for COVID-19 The Role of Different Types of Tests in the COVID-19 Pandemic	Dec 18, 2020	Emerging Health Technologies	Completed	EH0085-000
Connected Devices to Support Remote Examination and Diagnosis in Primary Care and Specialty Care		Dec 10, 2020	Emerging Health Technologies	Completed	EH0088-000

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 51 - 75 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
secukinumab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Jan 17, 2025	Reimbursement Review		Complete	SR0781-000
mirvetuximab soravtansine		Jan 17, 2025	Reimbursement Review		Pending	PC0394-000
teprotumumab	Patient and Clinician Group Input	Jan 17, 2025	Reimbursement Review		Active	SR0853-001
teprotumumab	Patient and Clinician Group Input	Jan 17, 2025	Reimbursement Review		Active	SR0853-000
belantamab mafodotin, pomalidomide, dexamethasone	Patient and Clinician Group Input	Jan 17, 2025	Reimbursement Review		Active	PC0380-000
faricimab	Draft Recommendation Patient and Clinician Group input	Jan 17, 2025	Reimbursement Review		Active	SR0832-000
daratumumab	Patient and Clinician Group input	Jan 17, 2025	Reimbursement Review		Active	PC0388-000
belantamab mafodotin, bortezomib, dexamethasone	Patient and Clinician Group Input	Jan 17, 2025	Reimbursement Review		Active	PC0379-000
Endometrial cancer	Scoping Document	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0076-000
Multiple myeloma	Scoping Document	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0074-000
Mesothelioma	Proposed Scope	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Feedback	PH0077-000
Prostate cancer	Proposed Scope	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0073-000
cabozantinib	Proposed Scope	Jan 16, 2025	Reimbursement Review		Active	PX0378-000
trabectedin	Proposed Scope	Jan 16, 2025	Reimbursement Review		Active	PX0377-000
Hodgkin lymphoma	Proposed Scope	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0079-000
cariprazine	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Jan 16, 2025	Reimbursement Review		Complete	SR0827-000
Diffuse large B cell lymphoma (DLBCL)	Proposed Scope	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0078-000
Renal cell carcinoma	Scoping Document	Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	Open for Stakeholder Input	PH0075-000
Urothelial carcinoma		Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	In Progress	PH0070-000
Myelofibrosis		Jan 16, 2025	Reimbursement Review	Provisional Funding Algorithm	In Progress	PH0069-000
nemolizumab		Jan 15, 2025	Reimbursement Review		Pending	SR0869-000
tofersen		Jan 15, 2025	Reimbursement Review		Pending	SR0883-000
Non-small-cell lung cancer (NSCLC)		Jan 15, 2025	Reimbursement Review	Provisional Funding Algorithm	In Progress	PH0071-000
zilucoplan	Draft Recommendation	Jan 15, 2025	Reimbursement Review		Active	SR0838-000
daridorexant	Patient and Clinician Group input	Jan 15, 2025	Reimbursement Review		Active	SR0862-000